Garcia de la Mària, CristinaCañas, María AlexandraFernández Pittol, MarianaDahl, AndersGarcía González, JavierHernández Meneses, MartaCuervo Requena, GuillermoMoreno, AsunciónMiró Meda, José M. (José María), 1956-Marco, Francesc2024-01-242024-02-102023-02-101744-8336https://hdl.handle.net/2445/206265IntroductionMethicillin-resistant and -susceptible Staphylococcus aureus (MRSA/MSSA) infections are a major global health-care problem. Bacteremia with S. aureus exhibits high rates of morbidity and mortality and can cause complicated infections such as infective endocarditis (IE). The emerging resistance profile of S. aureus is worrisome, and several international agencies have appealed for new treatment approaches to be developed.Areas coveredDaptomycin presents a rapid bactericidal effect against MRSA and has been considered at least as effective as vancomycin in treating MRSA bacteremia. However, therapy failure is often related to deep-seated infections, e.g. endocarditis, with high bacterial inocula and daptomycin regimens S. aureus infections have limitations in monotherapy. Daptomycin in combination with other antibiotics, e.g. fosfomycin, may be effective in improving clinical outcomes in patients with MRSA IE.Expert opinionExploring therapeutic combinations has shown fosfomycin to have a unique mechanism of action and to be the most effective option in preventing the onset of resistance to and optimizing the efficacy of daptomycin, suggesting the synergistic combination of fosfomycin with daptomycin is a useful alternative treatment option for MSSA or MRSA IE.38 p.application/pdfeng(c) Taylor and Francis, 2023Medicaments antibacteriansEndocarditisAntibacterial agentsEndocarditisinfo:eu-repo/semantics/other2024-01-24info:eu-repo/semantics/openAccess934069836744387